Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 92

Latest Posts

shutterstock 169298336

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

t cells cancer fusebulb fi

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

shutterstock 173237540

News and Trends 15 Nov 2016

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

gambling crispr investment drugs

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […]

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 10 Nov 2016

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […]

November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

shutterstock 94875625

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 245933788

News and Trends 9 Nov 2016

Up, up and away! CureVac’s money pile now Totals €325M

CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […]

November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

costantini ose immunotherapeutics

News and Trends 7 Nov 2016

Catching Up with the French Leader in Immuno-Oncology #BIOEurope

Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with the CEO, Dominique Costantini, at BIO Europe to make our first video Interview. OSE Immunotherapeutics is developing immunotherapy products against invasive and metastatic late-stage cancers. Memopi is one of its key technologies, and it is currently under development for ovarian, colon and breast […]

November 7, 2016 - 1 minutemin - By Philip Hemme

Screen Shot 2016 11 03 at 17.02.21

News and Trends 4 Nov 2016

This Company has developed a Personalized App to Fight Cancer

We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA. City: Charleroi, Belgium Founded: 2012 Employees: 11 – 50 Financial data: €7.7M raised in September to expand into the global market Mission: […]

November 4, 2016 - 1 minutemin - By Clara Rodríguez Fernández

shutterstock 308293001

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 135310529

News and Trends 31 Oct 2016

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 254632465

News and Trends 31 Oct 2016

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT